Theratechnologies Peptide-Drug Conjugate Shows Better Anti-Metastatic Activity Compared With Docetaxel Alone

by Vandana Singh, Benzinga Editor

June 21, 2021 11:38 AM | 1 min read |

Theratechnologies Inc THTX has announced new preclinical in vivo findings on its peptide-drug conjugate (PDC), TH1902.
The results demonstrate that TH1902 has better anti-metastatic activity when compared to docetaxel alone when administered at an equimolar concentration in a lung metastasis cancer model expressing the sortilin (SORT1) receptor.
The Company intends to present these findings at an upcoming scientific meeting.
The Company will host a webcast today at 11:00 a.m. ET to discuss its SORT1+ Technology and TH1902, which will include additional details on these preclinical findings.
Price Action: THTX shares are up 3.77% at $3.85 during the market trading session on the last check Monday.

Posted In: Biotech News Penny Stocks Health Care Small Cap General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.